Next Generation Therapeutics
for Mental Health Disorders

Advancing novel molecules designed to enhance brain plasticity
and address the limitations of current treatments
Discover how
Our goal is to lead the development of combination therapies that enhance neuroplasticity and improve psychiatric outcomes.
Once daily oral dosage form
No supervision
Designed for efficacy with minimal side effects

No interruption to daily lifestyle

Transforming mental health

Our lead drug candidate is a fixed-dose combination of an SSRI and a micro-dose of ibogaine – a central nervous system stimulant.
PsyRx develops novel combination drug therapies that enhance existing antidepressants through carefully calibrated low-dose active compounds. Our development strategy focuses on improving clinical outcomes without altering patient functionality or daily life.
Read more

Unleashing the therapeutic
potential of Ibogaine

IBOGAINE

 

Ibogaine is a powerful compound derived from the root bark of the iboga tree (Tabernanthe iboga), native to Central and West Africa.

Historically, it was marketed in France until the 1970s under the name Lambarène as a stimulant.

Today, ibogaine is at the forefront of cutting-edge research in the United States, being developed not only as a promising treatment for addiction but also for its potential to revolutionize depression therapy by enhancing neuroplasticity and addressing treatment-resistant cases.

Key Objectives

• Faster therapeutic onset
• Improved response in difficult-to-treat populations
• Reduced side-effect burden
• Improved patient adherence
Supplying GMP standard APIs of Ibogaine
and Psilocybin to pharmaceutical and
biotechnology companies
Clinical advantage - Faster onset,
alleviates mood and limits side effects.
Safer with lower burden on patients and
reduced financial cost of treatment.
Adding microdoses of Ibogaine or
Psilocybin to current psychiatric drugs
Regulatory advantage - Accelerated
regulatory approval process
Learn more

The natural pharmaceutical grade
psilocybin in 4 steps

1
Preparation of master
cell bank
First, we select the best psilocybin mushroom strains and prepare a master cell bank for a consistent manufacturing process, both currently and in the future
2
Mycelium isolation
For manufacturing a natural Psylocibin API batch, we grow specific mycelium from the master bank in a controlled bioreactor for 2 weeks
3
Extraction and isolation
(GMP process)
We extract the mushroom metabolites for a full spectrum extract followed by isolation of > 99% pure natural Psilocybin
4
Packaging and delivery
(GMP process)
We package and store our final product in a controlled environment, according to stability test validations and requirements until it is delivered to costumers

Pharmaceutical Manufacturing Platform

  • PsyRx has developed proprietary processes to produce pharmaceutical-grade active compounds, optimized for consistency, purity, and scalability.
    Platform characteristics

Leveraging existing know-how and technology

Controlled, GMP-aligned processes
Reproducible quality and yield
Scalable manufacturing suitable for late-stage development
Cost-efficient production design

Management

Itay Hecht
Business Development
Itay is an entrepreneur with vast experience in the private and public sectors. He oversaw the first IPO of medical Cannabis company in the Tel Aviv Stock Exchange. Prior to PsyRx Itay served as the CEO of Hi-Pharma Ltd, a medical cannabis company for 2 years and 7 years as COO of Palgi Sharon - Israeli Municipal Water Corporation.
Moshe Neuman, PhD
Regulatory Affairs
Over 27 years of experience in leading regulatory affairs consulting providing professional expert advice and integrated CRO services to Israeli startup companies at early-stage development, in the fields of pharmaceutical, biotechnology, medical devices.
Asher Holtzer, PhD
Co-founder, Board Member
Over 30 years' management experience in the medical device and biotech industry. Founded several successful bio-tech companies, including InspireMD (NYSE MKT: NSPR), UroGen Pharma (NASDAQ: URGN), part of the management team of Biosense – acquired by Johnson & Johnson in 1997.
Kobi Buxdorf, PhD
Co-founder, Board Member
Entrepreneur, founder of Cannador and Tincoli, Co founder of Wilk (TLV:WILK). Over 10 years of academic and industrial research and managing experience, in microbiology, molecular biology, plant sciences, diagnostics and medical devices. Extended background in regulation, business development and commercialization of basic science.
Prof. Moshe Kotler MD, M.HA
Medical Director
Professor emeritus of psychiatry at the Tel Aviv University School of Medicine. Served as the Deputy Dean (for medical education) of the Faculty of Medicine. Former Director of Be'er Ya'akov Mental Health Medical Center – Ness Ziona.

Board of Directors

Itamar Grotto
Executive Chairman
Asher Holtzer
CCO & Co Founder
Kobi Buxdorf
CTO & Co Founder
Itay Hecht
CEO & Co Founder

The next generation
of psychedelics is
already here

If you want to be a part of it,
we’d love to hear from you
Get In Touch





    Skip to content